| Time | Topic |
|---|---|
| 7:00 | Continental Breakfast and Registration |
| Section X: Angiogenesis in the Clinical Setting Chair: Laura Benjamin, Ph.D. |
|
| 8:20 am | Novel Designs and End Points for Phase II Clinical Trials Sudhakar Akulapalli, MSc., MPhill & Ph.D. |
| 8:40 am | The Reactive Oxygen Driven Tumor-Implications for Diagnosis and Treatment Jack Arbiser, M.D., Ph.D |
| 9:00 am | Anti-Angiogenic Therapy: Clinical Challenges Debabrata Mukhopadhyay, Ph.D. |
| 9:20 am | The Myeloma Conundrum: Roadmap or Distraction for the Treatment of Cancer? S. Vincent Rajkumar, M.D |
| 9:40 am | Anti-angiogenic Therapy in Melanoma Svetomir Markovic, M.D., Ph.D. |
| 10:00 am | Break |
| 10:30 a.m. | Adjuvant Hepatic Arterial Infusional Chemotherapy: Revisiting The Past or A New Era? Axel Grothey, M.D. |
| 10:50 am | Leukemic B Cell Interaction With Its Microenvironment: Implications for Therapy Neil Kay, M.D. |
| Section XI: Mayo Clinic Lectureship Chair: Philip Greipp, M.D. |
|
| 11:10 am | Introduction |
| 11:20 am | TBA Shaji Kumar, M.D. |
| 11:50 am | The Role of Angiogenesis Inhibitors in Central Nervous System Tumors Jan Buckner, M.D. |
| 12:20 pm | Closing Comments and Adjourn Debabrata Mukhopadhyay, Ph.D. |
